NEW YORK CITY, NY / ACCESS Newswire / September 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ:SLNO). Investors who purchased Soleno securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SLNO.
Investigation Details
On September 10, 2025, Soleno is the subject of a report published by Seeking Alpha, titled: "Soleno drops on death of patient treated with Vykat XR." The article explains, "According to the FDA’s Adverse Event Reporting database, the patient died in August due to pulmonary embolism after undergoing treatment with Vykat XR." Following this news, Soleno’s stock dropped more than 14.7% in afternoon trading on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Soleno securities, you can assist this investigation by visiting the firm’s site: bgandg.com/SLNO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_468706700/2457/2025-09-11T13:30:54